Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Ashvattha Therapeutics, Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units, so the current workload is divided between separate examination channels.
ROGERS, JAMES WILLIAM is the busiest examiner, with 1 pending matter. The distribution supports matter-specific response planning, with any shared approach based on the biotechnology and pharmaceutical subject matter rather than examiner continuity.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROGERS, JAMES WILLIAM | 1 | 46.1% | +22.4% |
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18825168 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYE | ROGERS, JAMES WILLIAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18825168 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYE | ROGERS, JAMES WILLIAM | — |
| 18444218 | DENDRIMER COMPOSITIONS AND METHODS FOR TREATMENT OF SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME | CHANDRA, GYAN | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18825168 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYE | ROGERS, JAMES WILLIAM | 1618 | §102§103Other | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18444218 | DENDRIMER COMPOSITIONS AND METHODS FOR TREATMENT OF SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME | CHANDRA, GYAN | 1674 | §103DP | Non-Final OA | — | Pending | Feb 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAshvattha Therapeutics, Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
James William Rogers has the most, with 1 of Ashvattha Therapeutics, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
